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Background: Cystic ﬁbrosis (CF) airways are nitric oxide (NO) deﬁcient. We studied safety and efﬁcacy of repeated inhalations of nebulized L-arginine,
the substrate for NO synthase (NOS), in patients with CF.
Methods: Double-blind, randomized, placebo-controlled crossover treatment trial of twice daily inhalation of 500 mg L-arginine for two weeks
compared to inhalation of saline in 19 CF patients (ClinicalTrials.gov Identiﬁer: NCT00405665).
Results: L-Arginine inhalation was well tolerated and resulted in a signiﬁcant increase in exhaled NO. FEV1 increased by an average of 56 ml
compared to −8 ml after saline solution; but this difference did not reach statistical signiﬁcance. Sputum concentrations of L-ornithine, the product
of arginase activity, increased signiﬁcantly while the L-ornithine derived polyamines did not. There was no change in inﬂammatory markers in
sputum.
Conclusion: Repeated inhalation of L-arginine in CF patients was safe and well tolerated. Inhaled L-arginine increased NO production without
evidence for changes in airway inﬂammation.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Nitric oxide; L-Arginine; Polyamines; Clinical trial; Airway inﬂammation1. Introduction
Nitric oxide (NO), which is important in the regulation of
airway smooth muscle tone, is formed from L-arginine by nitric
oxide synthases (NOSs). The availability of L-arginine for NOS
and the production of NO are reduced in cystic fibrosis (CF)
airways [1,2] Recent evidence also suggests that the competitive
NOS inhibitor asymmetric dimethylarginine (ADMA), which is
found in CF airways in high concentrations, contributes to the
known NO deficiency and increases the availability of L-arginine⁎ Corresponding author at: The Hospital for Sick Children, 555 University
Avenue, Toronto, Ontario, CanadaM5G 1X8. Tel.: +1 416 813 6346; fax: +1 416
813 6246.
E-mail address: hartmut.grasemann@sickkids.ca (H. Grasemann).
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http://dx.doi.org/10.1016/j.jcf.2012.12.008for arginase, an enzyme that also uses L-arginine as substrate [3].
The activity of arginase is increased in CF airway secretions, and
L-ornithine, the product of arginase activity, further reduces the
availability of L-arginine for intracellular NOS by competing for its
cellular uptake [2]. L-Ornithine is the precursor for polyamine
biosynthesis. The polyamines putrescine, spermidine and spermine
are present in CF airways in high concentrations and, while it
remains unclear what role polyamines play in CF lung disease,
there is evidence that spermine may contribute to airway smooth
muscle constriction [4,5]. While supplementation of L-arginine has
the potential to improve airway NO production and pulmonary
function in CF patients, an increase in L-arginine availability may
augment the production of L-arginine metabolites such as ADMA
or spermine with untoward side effects. In addition, the effect of
increased NO production on airway inflammation in CF has not
been defined.by Elsevier B.V. All rights reserved.
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airway NO production, as patients with better function were
found to have higher exhaled NO and sputum NOx levels
compared to those with poor lung function [6–8]. Antibiotic
treatment for a CF pulmonary exacerbation improves pulmo-
nary function and increases airway NO formation [2,3,9,10]. A
single inhalation of nebulized L-arginine transiently increased both
exhaled NO and FEV1 in one previous clinical study in CF
patients [11].We therefore conducted a double-blind, randomized,
placebo-controlled treatment trial to assess the safety and efficacy
of twice daily inhalation of L-arginine in CF patients. In this study
we tested the hypothesis that repeated doses of inhaled L-arginine
would: 1. improve airwayNO production and pulmonary function
in CF patients, and 2. be well tolerated and have a negligible effect
on airway inflammation.
2. Methods
This is a double-blind, randomized, placebo-controlled cross-
over treatment trial to assess the safety and efficacy of twice daily
inhalation of a 500 mg L-arginine solution for 2 weeks compared
to inhalation of saline solution matched for tonicity in 20 patients
with CF at the Hospital for Sick Children (ClinicalTrials.gov
identifier: NCT00405665). The study was approved by the
Institutional Research Ethics Board; written informed consent
was obtained in all cases.
Patients were eligible for this study if they had a confirmed
diagnosis of CF as defined by two or more clinical features of
CF and a documented sweat chloride concentration greater
than 60 mEq/L or two well characterized disease causing CFTR
gene mutations, were 14 years of age and older, clinically stable
at enrollment and had a FEV1 between 40% and 80% of predicted
values [12]. Exclusion criteria include a respiratory culture
positive for Burkholderia cepacia complex within the past
year or at screening, use of systemic corticosteroids (1 mg/kg
or ≥20 mg of prednisone per day) within 30 days of screening,
use of intravenous antibiotics or oral quinolones within 14 days
of screening, history of biliary cirrhosis, portal hypertension, or
splenomegaly on physical exam at screening or enrollment, other
major organ dysfunction, investigational drug use within 30 days
of screening, history of alcohol, illicit drug or medication abuse
within 1 year of screening, history of lung transplantation or
currently on lung transplant list, positive pregnancy test at
screening (performed on all post-menarche females), acute
respiratory symptoms including wheezing at the time of study,
inability to take any form of bronchodilator, peripheral oxygen
saturation below 95% on room air or currently receiving
supplemental oxygen therapy.
2.1. Intervention
A 10% L-arginine solution (5 ml) was administered by
inhalation twice daily for 14 days with crossover to 5 ml of
saline inhaled twice daily for 14 days in randomized sequence
using sequentially numbered containers assigned by the Sick
Kids Research pharmacy. The active treatment consisted of
L-arginine 250 mg/ml dispensed in 2.2 ml vials, from whichthe patient took 2 ml (500 mg) and diluted it with 3 ml of sterile
water to give 5 ml of a 100 mg/ml solution. A placebo of similar
osmolarity and appearance was formulated consisting of 2.2 ml
vials of 1110 mmol/L (2.6%) hypertonic saline. A PARI eFlow
prototype (PARI, Starnberg, Germany) was used for nebulization.
Participants and caregivers were blinded to treatment allocation.
The justification for this regimen was based on the tolerance
and safety of a previous trial on inhaled L-arginine in CF patients,
where a single dose of 1.3 g L-arginine was administered with the
same inhalation device [11]. The total volume of this solution was
18 ml and we reasoned that an additional daily inhalation was
only feasible if the volume does not exceed 5 ml per inhalation
for a twice daily regimen. We therefore opted to use a twice
daily inhalation of 5 ml of a 100 mg/ml solution resulting in
a cumulative daily dose of 1 g L-arginine.
The primary efficacy endpoint was the absolute change in
lung function, measured by the change in FEV1 from baseline
to completion of the 14 days treatment periods. Secondary
efficacy endpoints included absolute changes in FVC and in
FEV25–75 from baseline to completion of the 2 week treatment
periods, relative changes in these lung function parameters
from baseline to completion of the 2 week treatment period,
changes in exhaled NO as well as changes in L-arginine
metabolite concentrations and in inflammatory markers in
sputum including absolute neutrophil counts, neutrophil elastase
activity and interleukin (IL)-8.
Patients underwent a screening assessment that included a
history and physical examination, review of current medications,
spirometry and respiratory tract cultures for microbiology. The
enrolment visit occurred within 14 days of the screening visit. If all
eligibility criteria were still met, patient was randomized to a
treatment arm. A repeat visit was performed at day 15, the day after
the last inhalation of study medication. Subsequently, patients
entered a 4 week washout period before crossover into the second
treatment phase that was identical in scheduled visits to the first
phase of the study.
Participants performed spirometry according to ATS guide-
lines using a mass flow sensor (Vmax series, SensorMedics
Corporation, Yorba Linda, California, USA) at screening Day-14,
enrollment Day 1 and Day 15. The fraction of exhaled NO (FENO)
was measured using a chemiluminescence analyzer (Eco Physics
CLD 88 sp® NO analyzer, Dürnten, Switzerland) at Day 1, and
15. Single breath on-line measurements were performed at a
constant expiratory flow of 50 ml×min−1, (FENO 50) in
accordance with published ERS/ATS standards [13]. The
mean of three measurements within 15% variation are used
for analysis.
Participants supplied spontaneously expectorated sputum
specimens for the measurements of L-arginine metabolite
concentrations and markers of inflammation at screening Day 14,
enrollment Day 1 and Day 15. The amino acids L-arginine,
L-citrulline, and L-ornithine and ADMA were measured in
sputum supernatant using liquid chromatography tandem mass
spectrometry (LC/MS/MS), as recently described [3]. Quantifi-
cation of the putrescine, spermidine and spermine was performed
using LCMS, according to the method described by Byun et al.
[14]. Sputum Il-8 concentrations were measured by ELISA
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activity similar to previously reported [15].
2.2. Statistical analyses
Results were expressed as mean±standard error of the mean
(SEM), unless stated otherwise. Binary comparisons were made
with two-tailed student's t-test or Wilcoxon, where appropriate.
Paired t-test was used to compare results before and after treatment.
p-Valuesb0.05were considered significant. All statistical analyses
were conducted using GraphPad Prism 4.0c (Graphpad Software
Inc., La Jolla, CA USA).
We calculated the sample size required for testing using
L-arginine as the main exposure variable and FEV1 as the primary
outcome variable. Based on previous data of the single dose pilot
study [11] we estimated a treatment effect of 0.10 l for FEV1 with
a standard deviation of this difference of 0.13. Assuming a
significance level of 5% and a power of 90% sixteen patients
were required to complete the study. The final sample size was set
at 20 to allow for a 20% dropout rate.
3. Results
Nineteen patients completed the study. One patient, who
dropped out of the study in week one due to treatment burden, was
excluded from the final analysis. The baseline demographics are
given in Table 1. Fourteen patients were pancreatic insufficient
and 3 were treated with insulin for CFRD. Other medications
included azithromycin (n=4), other oral antibiotics (n=2), inhaled
tobramycin (n=13), dornase alfa (n=1), hypertonic saline (n=2),
salbutamol (n=18) and inhaled corticosteroids (n=11). No patient
was treated with systemic corticosteroids at the time of study.
3.1. Safety
Inhalation of the L-arginine and saline solutions was well
tolerated. There were no serious adverse events (SAEs). Adverse
events (AEs) were reported by 7 patients during the L-arginine
and 9 patients during the placebo phase, respectively (Table 2).
Adherence of study medication based on number of returned
vials was 87.5% in the L-arginine (mean of 25.4/28 vials used,Table 1
Baseline demographics of the study population.
N (female:male) 20 (8:12)
Age 23.2 (13–52) yrs
CFTR genotype
F508del/F508del
F508del/other
other or not determined
6
11
3
Pulmonary function (before 1st inhalation)
FVC
FEV1
FEF25–75
81.3 (55–100) %
67.6 (47–78) %
46.6 (15–78) %
Data for age (years) and pulmonary function (% predicted) are given as mean
(range).
CFTR cystic fibrosis conductance regulator, FVC forced vital capacity,
FEV1 forced expiratory volume in one second, FEF 25–75 forced expiratory
flows at 25–75% vital capacity.range 21–28 vials) and 86.1% in the placebo arm (mean of 24.1/
28 vials used, range 8–28 used).
3.2. Efficacy
Absolute FEV1 was increased after 14 days of arginine by an
average of 56 ml compared to −4.7 ml after placebo, however
this difference did not reach statistical significance (p=0.08,
paired t-test) (Fig. 1). The% change from baseline FVCwas 2.1±
1.6% vs. −2.8±1.3% and FEV1 was 3.6±2.3% vs. −1.2±2.1%
after treatment with L-arginine and placebo, respectively (p=0.06,
paired t-test, respectively) (Fig. 1). Similar trends were observed
when lung function was expressed as percent predicted; the
difference reached statistical significance for FVC (Table 3).
Mean peripheral oxygen saturation remained unchanged after
L-arginine (pre 97%, range 95–100%, post 97%, range 94–99%)
and placebo (pre 97%, range 95–99%, post 97%, range 92–
99%). Subjective changes in clinical status were also assessed
during visits. After 14 days of arginine inhalation 3 patients
reported improvement and two deterioration of clinical status,
while after placebo improvement or deterioration was reported by
1 patient, respectively.
3.3. Exhaled NO
After 14 days of inhaled L-arginine FENO (measured 12 h after
the last inhalation) was increased from baseline (13.6±2.8 ppb vs.
10.4±2.1, p=0.027, paired t-test). There was no change in FENO
after 14 days of placebo inhalation (11.6±2.8 vs. 12.4±2.7 ppb).
Comparison of the relative (%) change from baseline FENO was
also significantly different between the groups (arginine +35.9±
12.9% vs. placebo −6.2±8.5%, p=0.015, t-test) (Fig. 2).
3.4. Sputum microbiology
Qualitative sputum microbiology before and after 14 days of
inhalation was available for 13/19 patients for each treatment arm
(Table 4). While there was no statistically significant difference
in effect of treatment arm on qualitative sputum analyses (Fisher
exact test p=0.15), 2 patients showed clearance of PseudomonasTable 2
Incidence of adverse events.
Symptom L-Arginine
(number of events)
Placebo
(number of events)
Increased cough 3 4
Headache 2 2
Cold-like symptoms 2
Hoarseness 1
Wheeze 1
Itchy eye 1
Fever 1 1
Rash 1
Stomach ache 1
Nose bleed 1
Hives 1
Increased heart rate 1
Fig. 1. Changes in forced vital capacity (FVC) and forced expiratory volume in
1 s (FEV1) after 14 days of L-arginine or placebo inhalation. Data are expressed
as % change from baseline % predicted.
Fig. 2. Changes in the fraction of exhaled nitric oxide (FENO) after 14 days of
L-arginine or placebo inhalation. Data are expressed as % from respective
baseline. The increase in FENO after L-arginine was statistically significant (p=
0.027, paired t-test).
Table 4
Sputum microbiology results.
Before Cleared/Acquired
Arginine Placebo Arginine Placebo
P. aeruginosa 7 8 −2/+0 −0/+0
S. aureus 9 11 −0/+1 −1/+1
S. maltophilia 2 0 −2/+0 −0/+1
A. fumigatus 8 5 −2/+0 −1/+1
Total 25 24 −6/+1 −2/+3
Shown is the number of patients positive for respective pathogen before
treatment with inhaled L-arginine or placebo, as well as the number of patients
that cleared (−) or acquired (+) the respective pathogen during either treatment
period.
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(Table 4).
3.5. Inflammation
Inhaled L-arginine or placebo did not result in a significant
change in inflammatory markers in sputum (Table 5).
3.6. Sputum L-arginine and NO metabolites
Mean sputum concentrations of L-arginine (313.2±56.9 vs.
733.8±270.2 μmol/ml, pb0.05), L-citrulline (258.8±48.6 vs.
405.1±77.4 μmol/ml, p=0.015) and L-ornithine (230.5±47.2 vs.
448.0±98.1 μmol/ml, p=0.014) were significantly increased after
14 days of inhaled L-arginine. Sputum levels of the NOS inhibitor
ADMA (but not SDMA) were also increased after L-arginine
(1.56±0.33 vs. 2.17±0.41 μmol/ml, p=0.026) (Fig. 3). The ratios
of L-arginine/ADMA and arginine/ornithine, which can be used as
indices of arginine availability for NOS at a given L-arginine
concentration, were not altered after either treatment (data
not shown). L-Ornithine, the product of arginase activity, was
significantly increased in sputum after inhaled L-arginine (Fig. 3).Table 3
Pulmonary function in percent predicted before and after treatment.
Arginine
Pre Post
FVC 78.32 (55–103) 80.16 (51–107
FEV1 65.74 (47–87) 68.05 (48–90)
FEF25–75 49.00 (16–82) 48.27 (20–88)
Data shown are mean (range) forced vital capacity (FVC) forced expiratory volume in on
before (pre) and after (post) 14 days of treatment with inhaled L-arginine or placebo. *The polyamines putrescine, spermidine and spermine did not
change significantly during treatment (Table 6).
4. Discussion
In this double blind placebo controlled crossover study 14 days
of arginine inhalation BID was safe, resulted in an increase in
exhaled NO, produced positive trends in lung function but did not
result in an increase in sputum markers of inflammation.
Treatment effects were small, but this study was not powered to
demonstrate clinical efficacy of L-arginine. These results support
the concept that augmentation of airway NO could have beneficial
effects in CF patients.
The effect of L-arginine supplementation on CF airway
functionwas previously studied after oral, intravenous and inhaled
application. A single infusion of L-arginine (500 mg×kg−1) led to
a small but significant increase in FENO, however exhaled NOPlacebo
Pre Post
) 83.21 (51–113) 80.53 (51–110)*
68.84 (42–103) 67.84 (45–100)
50.80 (15–78) 54.30 (13–90)
e second (FEV1) and forced expiratory flows at 25–75% vital capacity (FEF 25–75)
pb0.05. Wilcoxon test comparing pre to post.
Table 5
Sputum inflammatory markers.
Arginine p-Value Placebo p-Value
Pre Post Pre Post
Interleukin 8
(ng/ml sputum)
172.0±30.3 173.0±31.1 0.974 188.1±44.6 187.7±38.2 0.983
Neutrophil elastase activity (Units) 1.93±0.39 2.48±0.48 0.108 2.00±0.42 1.97±0.55 0.945
Total cell counts
(×106)
43.9±14.4 62.7±19.0 0.304 38.1±14.3 35.6±10.03 0.782
Neutrophil counts (per gram mucus) 151.7±39.4 205.8±61.8 0.489 143.8±51.0 128.4±31.4 0.855
Data shown are mean±standard error of the mean. Paired comparisons were made between before (pre) and after (post) 14 days of treatment with inhaled L-arginine
or placebo, respectively. There were no significant changes.
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function did not change [16]. A single oral dose of L-arginine
(200 mg×kg−1) increased plasma and sputum concentrations
as well as FENO within 3 h [17]. While oral supplementation of
L-arginine (200 mg×kg−1 TID) for 6 weeks resulted in higher
FENO compared to the placebo group, the effect size was small
and no effect on pulmonary function was observed [17]. In
contrast, a single inhalation of 1.3 g of a nebulized 7% L-arginine
hydrochloride solution (600 mOsmol/kg, pH 5–6) doubled FENO,
improved peripheral oxygen saturation and FEV1 for up to 24 h
[11]; therefore inhalation therapy with L-arginine seems to be the
most promising strategy for augmenting NO production ion CF
airways.
One limitation of the current trial is the relatively small
number of patients studied. While FENO significantly increased
after inhaled L-arginine, the effect on pulmonary function wasFig. 3. Sputum amino acids and ADMA concentrations before and after 14 days
concentrations of L-arginine, L-citrulline, L-ornithine and ADMA (pb0.05, respectivsmall and did not reach statistical significance for FEV1. NO
production from NOS, assuming the enzyme expression remains
unchanged, depends on the presence of endogenous NOS
inhibitors and the availability of L-arginine for the enzyme.
After 14 days of L-arginine inhalation, there was a measurable
increase in the concentrations of the NOS inhibitor ADMA and
the L-arginine/ADMA ratio (NOS substrate over inhibitor), that is
decreased in CF patients and correlates with low airway NOx [3],
remained unchanged. Similarly, the concentration of L-ornithine,
the product of arginase activity, was also increased after L-arginine
supplementation. Consequently, the L-arginine/L-ornithine ratio,
which can be used as a marker of substrate availability for
NOS at a given L-arginine concentration, remained unchanged.
Thus, the potential effect of increased L-arginine concentrations is
counteracted by an increase in both L-ornithine, which competes
with L-arginine for transport into the cell, and ADMA, which actsof L-arginine or placebo inhalation. There was a significant increase in the
ely) after L-arginine but not placebo inhalation.
Table 6
Sputum polyamine concentrations before and after treatments.
Arginine p-Value Placebo p-value
Pre Post Pre Post
Putrescine 74.6±20.4 145.3±47.7 0.284 32.7±8.4 132.3±59.1 0.193
Spermidine 1.80±0.26 2.19±0.51 0.678 3.77±1.07 3.51±0.66 0.669
Spermine 13.7±3.4 17.3±4.3 0.174 11.1±2.9 12.8±2.7 0.309
Data shown are mean±standard error of the mean concentrations in (μmol/l). Paired comparisons were made between before (pre) and after (post) 14 days of
treatment with inhaled L-arginine or placebo, respectively. There was no significant change in any of the polyamines.
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increase substrate availability by both supplementing L-arginine
and inhibiting competing pathway may therefore increase the
efficacy of treatment.
Interestingly, despite the increase in FENO and L-citrulline,
which are also products of L-arginine conversion by NOS, there
was no change in sputum NO metabolite concentrations. Other
studies had already suggested this, as sputum NOx concentrations
are high in CF patients while FENO is normal or low [6,7,18]. This
would indicate that sputum NOx may not be a good surrogate
marker of NO production.
Inhalation of L-arginine was well tolerated. There were no
reported serious adverse events in this study. The number of
patients experiencing adverse events was not different between
treatment groups. Events that were reported more than once were
mild and included increased cough during the inhalation, headache
and cold-like symptoms. This was the first study assessing airways
inflammation during L-arginine treatment in CF. A previous study
of L-arginine supplementation in CF patients had used 5% arginine
hydrochloride solution in children with CF to assess its effect as a
metabolite [19]. The dose administered in this study is hard to
judge as an ultrasonic device was used which was not well
characterized regarding aerosol deposition and FENO was not
measured as an outcome measure to demonstrate that L-arginine
increased NO production. In this study inhalation was stopped in 5
of 24 children because of increased cough. Bronchoscopy was
performed 4–10 weeks after onset of inhalation and the authors
described reddening, edematous swelling of mucous membranes
and hypersecretion in 15 of 24 children. These findings were
interpreted to reflect clinical deterioration, although, FEV1 and
functional residual capacity (FRC) had increased during treatment
in most patients. Unfortunately, no markers of inflammation
were included in this study [19]. We believe that an alternative
explanation for the observed changes in bronchoscopy findings
could be hyperemia of the mucosa due to the dilatatory effect of
increased NO production. This is supported by the lack of a
significant increase in any sputum marker of airway inflamma-
tion in the present study.
The lack of NO in the CF airways could potentially contribute
to airways colonization with P. aeruginosa and an increase in
airwayNO productionmay result in improved bacterial killing, as
Pseudomonas is known to be sensitive to NO-mediated killing
[20]. Interestingly, in the study mentioned above eradication
of P. aeruginosa was observed after inhaled L-arginine in the
two patients who were positive at baseline [19]. In line with
this we observed clearance of P. aeruginosa after 2 weeks ofinhaled L-arginine in two patients, but further evidence is
needed to support these preliminary findings.
In summary, this study suggests that inhaled L-arginine is safe
and does not lead to increased airway inflammation in CF patients
and positive clinical trends were demonstrated. This supports the
design of an efficacy study assessing the long term effect of
inhaled L-arginine in CF. Alternative strategies to increase NO
concentrations in the airways would include the use of inhaledNO
[21], or the pharmaceutical inhibition of arginase which may
become available in the near future as specific inhibitors are in
pre-clinical testing [22,23].
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